The effects of empagliflozin on diuresis and natriuresis in patients with type 2 diabetes mellitus and liver cirrhosis
Up to 6 months' empagliflozin administration in patients with cirrhosis and T2DM seems safe and increases urine output and FE<sub>Na</sub>, but its impact on renal function requires further investigation. Larger randomized controlled trials are needed to confirm its long-term efficacy and safety in this setting.
Authors
- Christos Siafarikas (ORCID: https://orcid.org/0009-0000-9020-1962)
Institutions
- National and Kapodistrian University of Athens (GR)
- Laiko General Hospital of Athens (GR)
Publication Details
- Journal
- Annals of Gastroenterology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.20524/aog.2025.0992
- Primary Topic
- Diet and metabolism studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00